{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:13:29Z","timestamp":1790734409023,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>Prior investigations of the tumor microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) have shown that immune and stromal cells are key contributing factors to patients\u2019 outcome. However, challenges remain in finding reliable prognostic biomarkers based on cell infiltration. In this study, we attempted to shed some light on chemokine C\u2013C motif chemokine ligand 8 (CCL8) in DLBCL <jats:italic>via<\/jats:italic> interaction with M2 macrophages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm was applied to evaluate immune and stromal scores from transcriptomic profiles of 443 DLBCL samples from The Cancer Genome Atlas (TCGA) and GSE10846 datasets. Immune cell infiltration (ICI) clusters were obtained based on different immune cell infiltrations of each sample, and gene clusters were derived through differentially expressed genes (DEGs) between the distinct ICI clusters. Five immune-related hub genes related to overall survival (OS) and clinical stages were obtained by COX regression analysis and protein\u2013protein interaction (PPI) network construction then verified by quantitative real-time PCR (qPCR) and immunofluorescence staining in the FFPE tissues. The Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and TIMER websites were employed to explore the biological functions of CCL8-related DEGs. Uni- and multivariable Cox regression analyses were performed to analyze CCL8 as an independent prognostic risk factor in GSE10846 and were verified in other independent GEO cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A higher stromal score was associated with favorable prognosis in DLBCL. Patients in the ICI B cluster and gene B clusters had a better follow-up status with a higher programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) expression. Most of ICI-related DEGs were enriched for immune-related signaling pathways. Five hub genes with a distinct prognosis association were identified, including CD163, which is a biomarker of M2 macrophages, and CCL8. Abundant M2 macrophages were discovered in the high-CCL8 expression group. The functional analysis indicated that CCL8 is a key component of immune-related processes and secretory granule groups. Cox regression analysis and data from other GSE datasets yielded additional evidence of the prognostic value of CCL8 in DLBCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CCL8 has been implicated in macrophage recruitment in several solid tumors, and only a few reports have been published on the role of CCL8 in the pathogenesis of hematological malignancies. This article attempted to find out TME-related genes that associated with the survival in DLBCL patients. CCL8 was identified to be involved in immune activities. Importantly, a series of bioinformatics analysis indicated that CCL8 might become an effective target for DLBCL, which interacts with M2 macrophage and immune checkpoint. The potential related mechanisms need to be further elucidated.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.950213","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:28:01Z","timestamp":1661149681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoli","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiong","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1188246","article-title":"Large-Scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas","volume":"5","author":"Tosolini","year":"2016","journal-title":"Oncoimmunology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100822","article-title":"Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large b cell lymphoma","volume":"61","author":"Pi","year":"2022","journal-title":"Drug Resist Update"},{"key":"B3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijbiomac.2022.03.057","article-title":"A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors","volume":"207","author":"Aghanejad","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"Hopken","year":"2019","journal-title":"Trends Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00288","article-title":"Microenvironment cell contribution to lymphoma immunity","volume":"8","author":"Kumar","year":"2018","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836223","article-title":"Epigenetic modifications in tumor-associated macrophages: A new perspective for an old foe","volume":"13","author":"Niu","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","article-title":"Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer","volume":"39","author":"Hornburg","year":"2021","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Grunwald","year":"2021","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccell.2019.08.001","article-title":"Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention","volume":"36","author":"O'Connor","year":"2019","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0262-5","article-title":"PD-L1 over-expression is driven by b-cell receptor signaling in diffuse large b-cell lymphoma","volume":"99","author":"Wang","year":"2019","journal-title":"Lab Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/cancers12030603","article-title":"The application of deep learning in cancer prognosis prediction","volume":"12","author":"Zhu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large b-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtn.2020.08.030","article-title":"Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy","volume":"22","author":"Zhang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626818","article-title":"Understanding the immune-stroma microenvironment in b cell malignancies for effective immunotherapy","volume":"11","author":"Apollonio","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41467-018-04150-7","article-title":"A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression","volume":"9","author":"Farinello","year":"2018","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ebiom.2019.09.034","article-title":"Refining diffuse large b-cell lymphoma subgroups using integrated analysis of molecular profiles","volume":"48","author":"Dubois","year":"2019","journal-title":"EBioMedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse Large b-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cancers12071869","article-title":"New insights into diffuse Large b-cell lymphoma pathobiology","volume":"12","author":"Solimando","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.03.053","article-title":"Epstein-Barr Virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells","volume":"453","author":"Higuchi","year":"2019","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0786","article-title":"CXCL-8\/IL8 produced by diffuse Large b-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL","volume":"77","author":"Manfroi","year":"2017","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"CII","DOI":"10.1007\/s00262-022-03165-w","article-title":"Tafasitamab mediates killing of b-cell non-hodgkin's lymphoma in combination with gammadelta T cell or allogeneic NK cell therapy","author":"Her","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large b-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/- monocytes in b-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1393599","article-title":"B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity","volume":"7","author":"McKee","year":"2018","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12976","article-title":"Macrophage targeting: opening new possibilities for cancer immunotherapy","volume":"155","author":"Cassetta","year":"2018","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15179","article-title":"High PTX3 expression is associated with a poor prognosis in diffuse large b-cell lymphoma","volume":"113","author":"Carreras","year":"2022","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8941260","article-title":"Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response","volume":"2016","author":"Reiser","year":"2016","journal-title":"J Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.3390\/ijms21207619","article-title":"CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and chemokine receptors: New targets for cancer immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms21218412","article-title":"CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41419-019-1748-1","article-title":"Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1747340","article-title":"Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas","volume":"9","author":"Dancsok","year":"2020","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1458","article-title":"Ubiquitin-specific protease 6 functions as a tumor suppressor in Ewing sarcoma through immune activation","volume":"81","author":"Henrich","year":"2021","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.950213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:28:03Z","timestamp":1661149683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.950213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2022.950213"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.950213","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"950213"}}